Treatment of lipid disorders in obesity

References

• Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J. Clin. Endocrinol. Metab.89, 2569–2575 (2004).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat. Report5, 1–7 (2009).
   Google Scholar
• Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am. J. Cardiol.75, 45B–52B (1995).
   PubMed Web of Science ®Google Scholar
• Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology132, 2181–2190 (2007).
   PubMed Web of Science ®Google Scholar
• Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.28, 1225–1236 (2008).
   PubMed Web of Science ®Google Scholar
• Aguilera CM, Gil-Campos M, Canete R, Gil A. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin. Sci.114, 183–193 (2008).
   PubMed Web of Science ®Google Scholar
• Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J. Clin. Invest.113, 1582–1458 (2004).
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest.109, 1125–1131 (2002).
   PubMed Web of Science ®Google Scholar
• Yamashita H, Takenoshita M, Sakurai M et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl Acad. Sci. USA98, 9116–9121 (2001).
   PubMed Web of Science ®Google Scholar
• Hill MJ, Metcalfe D, McTernan PG. Obesity and diabetes: lipids, ‘nowhere to run to’. Clin. Sci.116, 113–123 (2009).
   PubMed Web of Science ®Google Scholar
• Van Linthout S, Foryst-Ludwig A, Spillmann F et al. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis210, 438–444 (2010).
   PubMed Web of Science ®Google Scholar
• De Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat. Clin. Pract. Endocrinol. Metab.4, 608–618 (2008).
   PubMedGoogle Scholar
• Magkos F, Mohammed BS, Mittendorfer B. Effect of obesity on the plasma lipioprotein subclass profile in normoglycemic and normolipidemic men and women. Int. J. Obes.32, 1655–1664 (2008).
   PubMed Web of Science ®Google Scholar
• Magkos F, Mittendorfer B. Gender differences in lipid metabolism and the effect of obesity. Obstet. Gynecol. Clin. N. Am.36, 245–265 (2009).
   PubMed Web of Science ®Google Scholar
• Mooradian AD, Albert SG, Hass MJ. Low serum HDL-cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines. Diabetes Obes. Metab.9, 441–443 (2007).
   Google Scholar
• Lindström T, Kechagias S, Carlsson M, Nystrom FH. Transient increase in HDL-cholesterol during weight gain by hyperalimentation in healthy subjects. Obesity19, 812–817 (2010).
   Google Scholar
• Mooradian AD, Haas MJ, Wehmeier KR, Wong NCW. Obesity-related changes in high-density lipoprotein metabolism. Obesity16, 1152–1160 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Y, McGillicuddy FC, Hindle CC et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation121, 1347–1355 (2010).
   Google Scholar
• Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet375, 1634–1639 (2010).
   PubMed Web of Science ®Google Scholar
• Williams KJ, Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr. Opin. Lipidol.21, 218–228 (2010).
   PubMed Web of Science ®Google Scholar
• Sørensen TIA, Virtue S, Vidal-Puig A. Obesity as a clinical and public health problem: is there a need for a new definition based on lipotoxicity effects? Biochim. Biophys. Acta1801, 400–404 (2010).
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP. Primary and secondary hypertriglyceridaemia. Curr. Drug Targets10, 336–343 (2009).
   PubMed Web of Science ®Google Scholar
• Duane WC. Cholesterol metabolism in familial hypertriglyceridemia: effects of obesity versus triglyceride level. J. Lab. Clin. Med.130, 635–642 (1997).
   Google Scholar
• Hole I, Aastveit AH, Hammar N, Jungner I, Walldius G. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein Mortality RISk study (AMORIS). Atherosclerosis213, 299–305 (2010).
   Google Scholar
• Kastelein JJ, van der Steeg WA, Holme I et al.; TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins and their ratios in relation to cardiovascular events with statin treatment. Circulation117, 3002–3009 (2008).
   PubMed Web of Science ®Google Scholar
• Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med.161, 1413–1419 (2001).
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Williams K, Contois JH et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes4(3), 337–345 (2011).
   PubMed Web of Science ®Google Scholar
• Sniderman A, Williams K, de Graaf J. Non-HDL C equals apolipoprotein B: except when it does not! Curr. Opin. Lipidol.21, 518–524 (2010).
   Google Scholar
• Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P et al. Body mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet373, 1083–1096 (2009).
   PubMed Web of Science ®Google Scholar
• Després JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr. Res. Rev.6, 137–159 (1993).
   PubMedGoogle Scholar
• Yu B-L, Zhao S-P, Hu J-R. Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obes. Rev.11, 560–567 (2009).
   Google Scholar
• Ståhlberg D, Rudling M, Angelin B et al. Hepatic cholesterol metabolism in human obesity. Hepatology25, 1447–1450 (1997).
   PubMed Web of Science ®Google Scholar
• Dixon JB, O’Brien P. A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m2. Int. J. Obes. Relat. Metab. Disord.25, 793–797 (2001).
   Google Scholar
• Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch. Intern. Med.153, 1093–1103 (1993).
   PubMedGoogle Scholar
• Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. Arch. Intern. Med.154, 401–410 (1994).
   PubMedGoogle Scholar
• Brown RJ, Lagor WR, Sankaranaravanan S et al. Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins. Circ. Res.107, 357–364 (2010).
   Google Scholar
• Pihlajamäki J, Gylling H, Miettinen TA, Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J. Lipid. Res.45, 507–512 (2004).
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Kostakou PM, Anagnostopoulou KK. Familial hypercholesterolemia and triglyceride metabolism. Int. J. Cardiol.147, 349–358 (2011).
   Google Scholar
• Hogue JC, Lamarche B, Gaudet D et al. Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis190, 429–435 (2007).
   Google Scholar
• Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a huGE association review. Am. J. Epidemiol.160, 421–429 (2004).
   PubMed Web of Science ®Google Scholar
• Gaudet D, Vohl M-C, Perron P et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation97, 871–877 (1998).
   Google Scholar
• Hopkins PN, Heiss G, Ellison RC et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation108, 519–523 (2003).
   PubMed Web of Science ®Google Scholar
• Van Himbergen TM, Otokozawa S, Matthan NR et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. Arterioscler. Thromb. Vasc. Biol.30, 113–120 (2010).
   Google Scholar
• Brouwers MCGJ, de Graaf J, van Greevenbroek MMJ, Schaper N, Stehouwer CDA, Stalenhoef AFH. Novel drugs in familial combined hyperlipidemia: lessons from Type 2 diabetes. Curr. Opin. Lipidol.21, 530–538 (2010).
   Google Scholar
• Van der Kallen CJ, Voors-Pette C, de Bruin TW. Abdominal obesity and expression of familial combined hyperlipidemia. Obes. Res.12, 2054–2061 (2004).
   Google Scholar
• Van der Vleuten GM, Veerkamp MJ et al. Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD. Atherosclerosis183, 355–360 (2005).
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA302, 412–423 (2009).
   PubMed Web of Science ®Google Scholar
• Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss and conditional cardiovascular risk factors. Obes. Rev.12, e282–e289 (2011).
   PubMed Web of Science ®Google Scholar
• Retterstøl K, Hennig CB, Iversen PO. Improved plasma lipids and body weight in overweight/obese patients with type III hyperlipoproteinemia after 4 weeks on a low glycemic diet. Clin. Nutr.28, 213–215 (2009).
   Google Scholar
• Loveman E, Frampton GK, Shepherd J et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol. Assess.15, 1–182 (2011).
   Web of Science ®Google Scholar
• Di Buono M, Hannah JS, Latzel LI, Jones PJH. Weight loss due to energy restriction suppresses cholesterol biosynthesis in overweight, mildly hypercholesterolemic men. J. Nutr.129, 1545–1548 (1999).
   Google Scholar
• Datillo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr.56, 320–328 (1992).
   PubMed Web of Science ®Google Scholar
• The LOOK AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with Type 2 diabetes mellitus. Arch. Intern. Med.170, 1566–1575 (2010).
   PubMed Web of Science ®Google Scholar
• Yatsuya H, Jeffery RW, Erickson DJ et al. Sex-specific HDL-cholesterol changes with weight loss and their association with anthropometric variables: the LIFE study. Obesity19, 429–435 (2011).
   Google Scholar
• Maraki MI, Aggelopoulou N, Christodoulou N et al. Lifestyle intervention leading to moderate weight loss normalizes postprandial triacylglycerolemia despite persisting obesity. Obesity19, 968–976 (2011).
   Google Scholar
• Nordmann AJ, Nordmann A, Briel M et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch. Intern. Med.166, 285–293 (2006).
   PubMed Web of Science ®Google Scholar
• Samaha FF, Foster GD, Makris AP. Low-carbohydrate diets, obesity, and metabolic risk factors for cardiovascular disease. Curr. Atheroscler. Rep.9, 441–447 (2007).
   PubMedGoogle Scholar
• Shai I, Schwarzfuchs D, Henkin Y et al.; for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med.359, 229–241 (2008).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Engl. J. Med.360, 859–873 (2009).
   PubMed Web of Science ®Google Scholar
• Foster GD, Wyatt HR, Hill JO et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet. Ann. Intern. Med.153, 147–157 (2010).
   PubMed Web of Science ®Google Scholar
• Westman EC, Yancy WS Jr, Olsen MK, Dudley T, Guyton JR. Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int. J. Cardiol.110, 212–216 (2006).
   PubMed Web of Science ®Google Scholar
• Seshadri P, Iqbal N, Stern L et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am. J. Med.117, 398–405 (2004).
   PubMed Web of Science ®Google Scholar
• Volek JS, Phinney SD, Forsythe CE et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids44, 297–309 (2009).
   PubMed Web of Science ®Google Scholar
• LeCheminant JD, Smith BK, Westman EC, Vernon MC, Donnelly JE. Comparison of a reduced carbohydrate and reduced fat diet for LDL, HDL, and VLDL subclasses during 9-months of weight maintenance subsequent to weight loss. Lipids Health Disease9, 54 (2010).
   Google Scholar
• Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM. Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. Am. J. Clin. Nutr.20, 23–32 (2009).
   Google Scholar
• Tay J, Brinkworth GD, Noakes M, Keogh J, Clifton PM. Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-cardohydrate diet in abdominally obese subjects. J. Am. Coll. Cardiol.51, 59–67 (2008).
   PubMed Web of Science ®Google Scholar
• Larsen TM, Dalskov SM, van Baak M et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N. Engl. J. Med.363, 2102–2113 (2010).
   PubMed Web of Science ®Google Scholar
• Vetter ML, Iqbal N, Volger S, Wadden TA. Long-term effects of low-carbohydrate versus low-fat diets in obese persons. Ann. Intern. Med.152, 334–335 (2010).
   PubMedGoogle Scholar
• Wu T, Gao X, Chen M, van Dam RM. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes. Rev.10, 313–323 (2009).
   PubMed Web of Science ®Google Scholar
• Shaw K, Gennat H, O’Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst. Rev.4, CD003817 (2006).
   PubMedGoogle Scholar
• Nakou ES, Filippatos TD, Kiortsis DN et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyeprlipidaemia. Expert Opin. Pharmacother.9, 3151–3158 (2008).
   PubMed Web of Science ®Google Scholar
• Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev. Cardiovasc. Ther.8(12), 1777–1796 (2010).
   PubMedGoogle Scholar
• Smith SR, Weissman NJ, Anderson CM et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med.363, 245–256 (2010).
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity19, 110–120 (2011).
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W et al.; SCOUT investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med.363, 905–917 (2010).
   PubMed Web of Science ®Google Scholar
• Després J-P. Drug treatment for obesity. BMJ322, 1379–1380 (2001).
   Google Scholar
• NIH Consensus Development Panel: Gastrointestinal surgery for severe obesity. Ann. Intern. Med.115, 956–961 (1991).
   PubMed Web of Science ®Google Scholar
• Yermilov I, McGory ML, Shekelle PW, Ko CY, Maggard MA. Appropriateness criteria for bariatric surgery: beyond the NIH guidelines. Obesity17, 1521–1527 (2009).
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Laneri M, Veronelli A et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity; their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc. Diabetol.8, 37 (2009).
   Google Scholar
• Sjöström L, Narbro K, Sjöström CD et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med.357, 741–752 (2007).
   PubMed Web of Science ®Google Scholar
• Sjöström L, Lindroos A-K, Peltonen M et al.; for the Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med.351, 2683–2693 (2004).
   PubMed Web of Science ®Google Scholar
• Wolf AM, Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes. Surg.17, 910–919 (2007).
   PubMed Web of Science ®Google Scholar
• Kim S, Richards WO. Long-term follow-up of the metabolic profiles in obese patients with Type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann. Surg.251, 1049–1055 (2010).
   PubMed Web of Science ®Google Scholar
• Pihlajamäki J, Grönlund S, Simonen M et al. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism59, 866–872 (2010).
   PubMed Web of Science ®Google Scholar
• Hofsø D, Nordstrand N, Johnson LK et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur. J. Endocrinol.163, 735–745 (2010).
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Swarbrick MM, Schaefer EJ et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodelling in obese women. J. Lipid Res.51(8), 2405–2412 (2010).
   PubMed Web of Science ®Google Scholar
• Laimer MW, Engl J, Tschoner A et al. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids44, 1125–1130 (2009).
   PubMedGoogle Scholar
• Grundy SM, Cleeman JI, Merz CNB et al.; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Silventoinen K, Magnusson PK, Neovius M et al. Does obesity modify the effect of blood pressure on the risk of cardiovascular disease? A population-based cohort study of more than one million Swedish men. Circulation118, 1637–1642 (2008).
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Jamal M, Wenger R, Heitshusen D, Liao J, Samuel I. Resolution of hyperlipidemia follows surgical weight loss in patients undergoing Roux-en-Y gastric bypass surgery: a 6-year analysis of data. Surg. Obes. Relat. Dis.7(4), 473–479 (2011).
   Google Scholar
• Skottheim IB, Stormark K, Christensen H et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin. Pharmacol. Ther.86, 311–318 (2009).
   PubMed Web of Science ®Google Scholar
• Skottheim IB, Jakobsen GS, Stormark K et al. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin. Pharmacol. Ther.87, 699–705 (2010).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 1760 000 participants in 26 randomised trials. Lancet376, 1670–1681 (2010).
   PubMed Web of Science ®Google Scholar
• Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann. Intern. Med.152, 69–77 (2010).
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Howard BV, Davidson M et al. Lipoprotein management in patients with cardiometabolic risk. Diabetes Care31, 811–822 (2008).
   PubMed Web of Science ®Google Scholar
• Deedwania P, Barter P, Carmena R et al. Reduction of low-density-lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets Study. Lancet368, 919–928 (2006).
   PubMed Web of Science ®Google Scholar
• Hoenig MR, Kostner KM, Read SJ, Walker PJ, Atherton JJ. Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr. Metab. Immune Disorder Drug Targets7, 153–166 (2007).
   Google Scholar
• Hoenig MR, Sellke FW. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis211, 260–265 (2010).
   Google Scholar
• Miettinen TA, Gylling H, Strandberg T, Sarna S; for the Finnish 4S Investigators. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. BMJ316, 1127–130 (1998).
   PubMed Web of Science ®Google Scholar
• Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman RR. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in Type 2 diabetes: a randomized placebo controlled factorial trial. Atherosclerosis213(2), 512–517 (2010).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis210, 353–361 (2010).
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med.362, 1563–1574 (2010).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye K-A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol.28, 39–46 (2008).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357, 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Christopher P. Cannon CP, Shah S Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med.363(25), 2406–2415 (2010).
   Google Scholar
• Greeve J. Inhibition of the synthesis of apolipoprotein B-containing lipoproteins. Hanb. Exp. Pharmacol.170, 483–517 (2005).
   Google Scholar
• Filion KB, El Khoury F, Beilinski M, Schiller I, Dendukuri N, Brophy JM. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord.10, 24 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen JD, Cziraky MJ, Cai Q et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006. Am. J. Cardiol.106, 969–975 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen D. Rosiglitazone: what went wrong? BMJ341, c4848 (2010).
   Google Scholar